Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 108.70
+2.40 (2.26%)
Sep 30, 2026, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.81B CNY in the half year ending June 30, 2026, with 76.21% growth. This brings the company's revenue in the last twelve months to 3.45B, up 37.43% year-over-year. In the year 2025, Akeso had annual revenue of 3.06B with 43.90% growth.
Revenue (ttm)
3.45B CNY
Revenue Growth
+37.43%
P/S Ratio
25.14
Revenue / Employee
845.28K CNY
Employees
4,082
Market Cap
100.13B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Shanghai Junshi Biosciences | 3.49B |
Akeso News
- 3 days ago - Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer - PRNewsWire
- 10 days ago - Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals - CNBC
- 14 days ago - Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate - PRNewsWire
- 17 days ago - Big Pharma Is Pouring Billions Into China's Biotechs - Barrons
- 18 days ago - Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 - PRNewsWire
- 4 weeks ago - Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's - PRNewsWire
- 5 weeks ago - Akeso Earnings release: H1 2026 - Filings
- 5 weeks ago - Akeso Quarterly report: H1 2026 - Filings